https://atamyo.com/press-releases/atamyo-therapeutics-submits-cta-in-europe-for-ata-100-its-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2i-r9/ 2021-10-26T09:05:07+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-depose-une-demande-dautorisation-dessai-clinique-en-europe-pour-ata-100-sa-therapie-genique-destinee-a-traiter-la-dystrophie-musculaire-des-ceintures-de-type-2i-r9/ 2021-10-26T09:05:26+00:00 monthly 0.2 https://atamyo.com/press-releases/2021/atamyo-therapeutics-obtains-first-regulatory-authorization-in-europe-to-initiate-a-clinical-trial-for-ata-100-its-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2i-r9/ 2021-12-06T14:33:12+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-obtient-une-premiere-autorisation-reglementaire-en-europe-pour-demarrer-un-essai-clinique-pour-ata-100-sa-therapie-genique-destinee-a-traiter-la-dystrophie-musculaire-des-ceinture/ 2022-02-24T09:57:45+00:00 monthly 0.2 https://atamyo.com/press-releases/2022/atamyo-therapeutics-franchit-dimportantes-etapes-reglementaires-et-financieres-pour-ata-100-sa-therapie-genique-destinee-a-traiter-la-dystrophie-musculaire-des-ceintures-de-type-2i-r9/ 2022-02-24T11:18:43+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-reaches-significant-regulatory-and-financial-milestones-for-ata-100-its-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2i-r9/ 2022-02-24T11:19:22+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-announces-significant-milestones-for-ata-100-and-ata-200-its-gene-therapy-programs-to-treat-limb-girdle-muscular-dystrophy-2i-r9-and-2c-r5/ 2022-05-16T12:22:11+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-annonce-des-presentations-scientifiques-cles-sur-ses-programmes-lgmd/ 2026-04-14T11:02:58+00:00 monthly 0.2 https://atamyo.com/press-releases/key-scientific-lgmd-programs/ 2022-09-06T15:39:58+00:00 monthly 0.2 https://atamyo.com/press-releases/2022/atamyo-therapeutics-annonce-le-traitement-dun-premier-patient-avec-sa-therapie-genique-ata-100-dans-lessai-clinique-ciblant-la-myopathie-des-ceintures-lgmd-r9/ 2022-09-26T09:34:15+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-announces-first-patient-dosed-with-ata-100-gene-therapy-in-lgmd-r9-clinical-trial/ 2026-02-10T16:35:30+00:00 monthly 0.2 https://atamyo.com/press-releases/https-atamyo-com-wp-content-uploads-gene-therapy-pioneer-roger-hajjar-joins-atamyo-therapeutics-board-pr-july-24-2023-pdf/ 2023-09-06T10:24:09+00:00 monthly 0.2 https://atamyo.com/non-classe/roger-hajjar-md-pionnier-de-la-therapie-genique-rejoint-le-board-datamyo-therapeutics/ 2026-04-14T11:02:30+00:00 monthly 0.2 https://atamyo.com/press-releases/2023/ind-for-ata-100-a-gene-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9-lgmd2i-r9-cleared-to-proceed-by-fda/ 2026-02-10T16:35:21+00:00 monthly 0.2 https://atamyo.com/press-releases/2023/https-atamyo-com-wp-content-uploads-cp-19-septembre-2023-ata-200-franchit-des-etapes-cles-avec-cta-en-europe-et-financement-france2030-pdf/ 2023-09-19T10:02:55+00:00 monthly 0.2 https://atamyo.com/press-releases/https-atamyo-com-wp-content-uploads-pr-sept-19-2023-ata-200-reaches-key-milestones-with-cta-in-europe-and-france2030-financing-pdf/ 2026-02-10T16:35:11+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-announces-participations-in-conferences-and-key-scientific-communications-on-its-lgmd-programs/ 2026-02-10T16:35:03+00:00 monthly 0.2 https://atamyo.com/press-releases/2023/atamyo-therapeutics-annonce-sa-participation-a-plusieurs-conferences-et-des-communications-scientifiques-cles-sur-ses-programmes-lgmd/ 2023-09-29T10:53:24+00:00 monthly 0.2 https://atamyo.com/press-releases/first-clinical-results-of-ata-100-a-gene-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9-lgmd2i-r9-presented-at-esgct/ 2026-02-10T16:34:56+00:00 monthly 0.2 https://atamyo.com/press-releases/2023/premiers-resultats-cliniques-ata-100-une-therapie-genique-pour-le-traitement-de-la-dystrophie-musculaire-des-ceintures-de-type-2i-r9-lgmd-2i-r9-presentes-au-congres-esgct/ 2023-10-26T14:53:29+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-obtains-regulatory-authorization-in-europe-to-initiate-a-clinical-trial-for-ata-200-its-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2c-r5/ 2026-02-10T16:34:42+00:00 monthly 0.2 https://atamyo.com/press-releases/press-releases-2024/atamyo-therapeutics-obtient-les-autorisations-reglementaires-en-europe-pour-lancer-lessai-clinique-de-ata-200-sa-therapie-genique-pour-traiter-la-myopathie-des-ceintures-lgmd-2c-r5/ 2024-03-26T08:41:53+00:00 monthly 0.2 https://atamyo.com/non-classe/atamyo-therapeutics-announces-scientific-communications-on-its-lgmd-programs-and-participation-in-conferences/ 2026-04-14T11:02:23+00:00 monthly 0.2 https://atamyo.com/press-releases/press-releases-2024/atamyo-therapeutics-annonce-des-presentations-scientifiques-sur-ses-programmes-lgmd-et-sa-participation-a-des-conferences/ 2024-04-22T09:58:16+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-obtains-us-fda-fast-track-designation-for-ata-100-a-gene-therapy-in-phase-1-2-clinical-trials-for-limb-girdle-muscular-dystrophy-type-r9-lgmd-r9/ 2026-02-10T16:34:24+00:00 monthly 0.2 https://atamyo.com/non-classe/atamyo-therapeutics-obtient-la-designation-fast-track-de-la-fda-americaine-pour-ata-100-therapie-genique-en-essai-clinique-de-phase-1-2-pour-la-dystrophie-musculaire-des-ceintures-de-type-r9-lgmd-r9/ 2024-06-24T09:34:46+00:00 monthly 0.2 https://atamyo.com/press-releases/press-releases-2024/la-dion-foundation-et-atamyo-therapeutics-annoncent-un-partenariat-pour-etendre-aux-etats-unis-lessai-clinique-datamyo-sur-la-therapie-genique-ata-200-pour-traiter-la-myopathie-des-c/ 2024-09-04T09:41:29+00:00 monthly 0.2 https://atamyo.com/press-releases/the-dion-foundation-and-atamyo-therapeutics-announce-a-partnership-to-expand-into-the-us-atamyos-clinical-trial-of-ata-200-gene-therapy-to-treat-limb-girdle-muscular-dystrophy-type-2c-r5/ 2026-02-10T16:34:15+00:00 monthly 0.2 https://atamyo.com/non-classe/professor-isabelle-richard-has-received-the-fifth-annual-lgmd2i-pioneer-award-from-cure-lgmd2i-foundation-and-the-speak-foundation/ 2026-02-10T16:34:08+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-to-provide-corporate-overviews-and-updates-on-its-pipeline-progress-at-6-upcoming-conferences-in-the-us-and-europe/ 2026-04-14T11:03:03+00:00 monthly 0.2 https://atamyo.com/press-releases/press-releases-2024/atamyo-therapeutics-presentera-un-update-corporate-et-les-avancees-de-son-pipeline-lors-de-6-conferences-a-venir-aux-etats-unis-et-en-europe/ 2024-09-16T13:33:19+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-observes-lgmd-awareness-day-with-updates-on-key-milestones-in-its-clinical-development-of-gene-therapies-for-patients-suffering-from-limb-girdle-muscular-dystrophies/ 2026-02-10T16:33:51+00:00 monthly 0.2 https://atamyo.com/press-releases/ind-for-ata-200-a-gene-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2c-r5-lgmd2c-r5-cleared-to-proceed-by-fda/ 2026-02-10T16:33:45+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-obtient-lautorisation-reglementaire-aux-etats-unis-pour-lessai-clinique-de-ata-200-sa-therapie-genique-pour-traiter-la-myopathie-des-ceintures-lgmd-2c-r5/ 2024-11-12T09:57:59+00:00 monthly 0.2 https://atamyo.com/press-releases/2025/atamyo-finalise-letude-de-choix-de-dose-dans-la-myopathie-des-ceintures-de-type-r9-lgmd-r9-et-obtient-la-designation-de-maladie-pediatrique-rare-de-la-fda-americaine-pour-ata-100/ 2025-04-03T12:29:18+00:00 monthly 0.2 https://atamyo.com/press-releases/2025/atamyo-completes-the-dose-finding-study-in-limb-girdle-muscular-dystrophy-type-r9-lgmd-r9-and-obtains-us-rare-pediatric-disease-designation-for-ata-100/ 2025-04-03T12:46:43+00:00 monthly 0.2 https://atamyo.com/press-releases/2025/atamyo-therapeutics-annonce-le-traitement-des-premiers-patients-avec-sa-therapie-genique-ata-200-dans-lessai-clinique-ciblant-la-myopathie-des-ceintures-lgmd-r5/ 2025-06-02T11:40:55+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-announces-first-patients-dosed-with-ata-200-gene-therapy-in-lgmd-r5-clinical-trial/ 2026-04-14T11:03:07+00:00 monthly 0.2 https://atamyo.com/press-releases/atamyo-therapeutics-announces-first-three-patients-dosed-with-ata-200-gene-therapy-in-on-going-lgmd-r5-clinical-trial-and-extension-of-partnership-with-the-dion-foundation/ 2026-02-03T10:02:32+00:00 monthly 0.2 https://atamyo.com/press-releases/2026/atamyo-therapeutics-announces-the-dosing-of-a-fourth-patient-with-ata-200-in-an-ongoing-lgmd-r5-clinical-trial-supported-by-curescg/ 2026-02-16T10:08:03+00:00 monthly 0.2 https://atamyo.com/press-releases/2026/mda-conference-2026-atamyo-therapeutics-presente-des-resultats-prometteurs-chez-les-premiers-patients-traites-avec-sa-therapie-genique-ata-200-dans-lessai-clinique-ciblant-la-myopathie-des/ 2026-03-09T10:06:47+00:00 monthly 0.2 https://atamyo.com/press-releases/2026/mda-conference-2026-atamyo-therapeutics-presents-promising-results-in-the-first-patients-treated-with-its-ata-200-gene-therapy-in-the-clinical-trial-targeting-lgmd-r5-limb-girdle-muscular-dystrophy/ 2026-04-14T11:02:36+00:00 monthly 0.2